RecruitingNot ApplicableNCT07113470

Response to Combined Trigeminal and Occipital Nerve Stimulation for the Preventive Treatment in Chronic Cluster Headache

Response to Combined Trigeminal and Occipital Nerve Stimulation for the Preventive Treatment in Chronic Cluster Headache: The RESPONSE-II Study


Sponsor

Salvia BioElectronics

Enrollment

10 participants

Start Date

Mar 17, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This is a limited open-label study being performed at two centers in the Netherlands. All participants will receive the same treatment, and both the patients and doctors will know what that treatment is. The goal is to see how safe and effective the PRIMUS system is for preventing Chronic Cluster Headaches (CCH) in people who haven't responded well to the drug verapamil. The study will also look at the patients' experience using the system.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Able and willing to provide informed consent
  • 18 years of age or older
  • Documented Primary Chronic Cluster Headache, for at least 1 year as per ICHD-3 criteria

Exclusion Criteria2

  • Any other chronic primary or secondary headache disorder, unless they can clearly differentiate them from cluster headache attacks based on the quality and associated symptoms
  • Secondary Cluster Headache

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEThe Salvia PRIMUS implantable neurostimulator System

The Salvia PRIMUS implantable neurostimulator System is designed to provide subcutaneous neurostimulation to the V1 branches of the Trigeminal nerves (supra-orbital and supra-trochlear nerves) and the branches of the Greater Occipital Nerves. It is intended to modulate headaches' neural networks by utilizing mild electrical pulses. There are 2 stimulation waveforms options: the Salvia burst waveform providing paresthesia-free stimulation and Tonic waveform, providing paresthesia-provoking stimulation. The PRIMUS System comprises a 25 cm (forehead) and a 17cm (back of the head) subcutaneous implant, a MySalvia device, a programmer, and surgical tooling.


Locations(1)

LUMC Leids Universitair Medisch Centrum

Leiden, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07113470


Related Trials